BSTC Share Price

Open 50.24 Change Price %
High 51.25 1 Day -0.02 -0.04
Low 50.24 1 Week -1.89 -3.60
Close 50.63 1 Month -1.42 -2.73
Volume 11805 1 Year 12.36 32.30
52 Week High 58.21
52 Week Low 31.32
BSTC Important Levels
Resistance 2 51.57
Resistance 1 51.18
Pivot 50.71
Support 1 50.08
Support 2 49.69
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

BioSpecifics Technologies Corp (NASDAQ: BSTC)

BSTC Technical Analysis 2
As on 22nd Feb 2017 BSTC Share Price closed @ 50.63 and we RECOMMEND Buy for LONG-TERM with Stoploss of 42.99 & Strong Sell for SHORT-TERM with Stoploss of 52.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
BSTC Target for February
1st Target up-side 55.69
2nd Target up-side 58.78
3rd Target up-side 61.87
1st Target down-side 46.89
2nd Target down-side 43.8
3rd Target down-side 40.71
BSTC Other Details
Segment EQ
Market Capital 101002608.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biospecifics.com
BSTC Address
BSTC
35 Wilbur Street
Lynbrook, NY 11563
United States
Phone: 516-593-7000
Fax: 516-593-7039
Interactive Technical Analysis Chart BioSpecifics Technologies Corp ( BSTC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioSpecifics Technologies Corp
BSTC Business Profile
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for clinical indications in Dupuytren’s contracture, Peyronie’s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including lipomas and cellulite. Auxilium has an agreement with Pfizer, Inc. (Pfizer), pursuant to which Pfizer has the right to market XIAFLEX for Dupuytren’s contracture and Peyronie’s disease in 27 member countries of the European Union and 19 other European and Eurasian countries, and under the registered trademark XIAPEX (collagenase clostridium histolyticum).